title: [Immunogenetic factors of interaction of hepatitis C virus and human and possibilities of development of therapeutic tactic].
abstract: Various macroorganism factors influence spontaneous and therapy induced elimination of hepatitis C virus. Standard therapy is application of a combination of pegylated interfernos and ribavirin. However such tactics results in attainment of a resistant virological response in approximately half the cases during infection by genotype 1 virus. The future of viral hepatitis C therapy lies most probably in the sphere of application of specific antiviral preparations such as protease and/or polymerase inhibitors as an addition to standard therapy. The aim of this review was to describe mechanisms of resistance to therapy in light of reaction of innate and adaptive immune response as well as an attempt to determine factors capable of prognosing response to therapy
authors.forename: N V
authors.initials: NV
authors.lastname: Fedoseeva
authors.forename: O O
authors.initials: OO
authors.lastname: Znoĭko
authors.forename: N D
authors.initials: ND
authors.lastname: Iushchuk
mesh_terms: D056704:Adaptive Immunity / Q000235:genetics; D000998:Antiviral Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D019468:Disease Management; D024882:Drug Resistance, Viral / Q000187:drug effects; D016174:Hepacivirus / Q000235:genetics* / Q000276:immunology*; D019698:Hepatitis C, Chronic / Q000235:genetics* / Q000276:immunology* / Q000628:therapy / Q000821:virology; D054884:Host-Pathogen Interactions; D006801:Humans; D007113:Immunity, Innate / Q000235:genetics; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D011092:Polyethylene Glycols / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000627:therapeutic use; D012254:Ribavirin / Q000627:therapeutic use
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a